Glucagon-like peptide-1 (GLP-1) receptor agonists were originally developed to treat people with type 2 diabetes, entering clinical use in the mid-2000s
Now we need to make sure they are used the way people deserve: thoughtfully, compassionately, responsibly, and with a plan for lasting weight loss
Adoptive cellular therapy using engineered macrophages represents another innovative approach to overcome MDSC-mediated immunosuppression
All authors give our consent for the article to be published in Scientific Reports
Moreover, fourteen articles had an unclear risk of selection bias for random sequence generation and allocation concealment [11, 15, 19, 24, 26, 27, 30, 32, 39,40,41,42, 46, 47], thirteen articles presented unclear risk of bias for blinding [15, 19, 24, 28, 31, 32, 36,37,38, 41, 44, 46, 47], while three articles showed an unclear risk for attrition bias, reporting bias and other sources of bias [23, 27, 31]
SS: Screening and selection of studies, proofreading/correcting manuscript assisting in drawing conclusions from the extracted data